Partner of choice in specialty, hospital, and rare disease medicines
Close working relationships
As highly experienced teams with significant commercial and medical knowledge, we pride ourselves on our close working relationship with our partners, manufacturers and customers as well as with healthcare professionals within the hospitals sector in Europe across key therapy areas including Anti-infectives and Endocrinology – something we are very much looking to build upon as we continue to grow the business in Europe.
Proud heritage and successful track record
We have a proud heritage and successful track record of business and product acquisitions. Most recently we completed the acquisition of a portfolio of Alprostadil products from UCB and acquired Correvio Pharma in 2020, increasing our European presence, strengthening our positioning as a trusted partner when commercialising hospital medicines in Europe together with establishing a robust foundation to continue our growth trajectory.
Actively on the lookout for new growth drivers
We continue to invest in our pipeline and aim to add considerably to our portfolio of complex medicines over the next few years with the launch of promising pipeline assets in 2021 and beyond.
We are constantly on the lookout for products that fit our brand and portfolio that provide clear value to patients and healthcare providers.